Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toni M Brand

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer Biology & Therapy|July 5, 2011
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximabToni M Brand, Emily F Dunn, Mari Iida, et al.
Cancer Research|May 25, 2018
BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCCBrandon Leonard, Toni M Brand, Rachel A O'Keefe, et al.
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabMari Iida, Toni M Brand, Megan M Starr, et al.
Molecular Cancer|December 30, 2025
Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Molecular Cancer Therapeutics|April 3, 2019
Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast CancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Molecular Cancer Therapeutics|March 18, 2014
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Cancer Research|August 20, 2014
AXL mediates resistance to cetuximab therapyToni M Brand, Mari Iida, Andrew P Stein, et al.
Science Signaling|January 5, 2017
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptorToni M Brand, Mari Iida, Kelsey L Corrigan, et al.
Science Signaling|November 9, 2021
RetractionToni M Brand, Mari Iida, Kelsey L Corrigan, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer Biology & Therapy|July 5, 2011
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximabToni M Brand, Emily F Dunn, Mari Iida, et al.
Cancer Research|May 25, 2018
BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCCBrandon Leonard, Toni M Brand, Rachel A O'Keefe, et al.
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabMari Iida, Toni M Brand, Megan M Starr, et al.
Molecular Cancer|December 30, 2025
Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Molecular Cancer Therapeutics|April 3, 2019
Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast CancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Molecular Cancer Therapeutics|March 18, 2014
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Cancer Research|August 20, 2014
AXL mediates resistance to cetuximab therapyToni M Brand, Mari Iida, Andrew P Stein, et al.
Science Signaling|January 5, 2017
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptorToni M Brand, Mari Iida, Kelsey L Corrigan, et al.
Science Signaling|November 9, 2021
RetractionToni M Brand, Mari Iida, Kelsey L Corrigan, et al.
Pageof 4